TY - JOUR
T1 - Efficacy and safety of ideglira in older patients with type 2 diabetes
AU - Lingvay, Ildiko
AU - Handelsman, Yehuda
AU - Linjawi, Sultan
AU - Vilsbøll, Tina
AU - Halladin, Natalie
AU - Ranc, Kristina
AU - Liebl, Andreas
N1 - Publisher Copyright:
Copyright © 2019 AACE.
PY - 2019/2
Y1 - 2019/2
N2 - Objective: The efficacy and safety of insulin degludec/ liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods: A post hoc analysis compared results of patients aged ≥65 versus <;65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <;65 and 87 patients aged ≥65 years from DUAL II, 326 patients <;65 years and 112 patients ≥65 years from DUAL III, and 412 patients <;65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V). Results: In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, −1.0% [−1.5; −0.6]95% confidence interval [CI], −0.8% [−1.0; −0.5]95% CI, and −0.9% [−1.3; −0.6]95%CI) for DUAL II, V, and III, respectively; all P<;.001). These mirrored results of patients <;65 years of age. Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]95% CI [P = .242]; 0.3 [0.1; 0.5]95% CI [P<;.001], and 11.8 [3.3; 42.8]95% CI [P<;.001] for DUAL II, V, and III, respectively). Conclusion: Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.
AB - Objective: The efficacy and safety of insulin degludec/ liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods: A post hoc analysis compared results of patients aged ≥65 versus <;65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <;65 and 87 patients aged ≥65 years from DUAL II, 326 patients <;65 years and 112 patients ≥65 years from DUAL III, and 412 patients <;65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V). Results: In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, −1.0% [−1.5; −0.6]95% confidence interval [CI], −0.8% [−1.0; −0.5]95% CI, and −0.9% [−1.3; −0.6]95%CI) for DUAL II, V, and III, respectively; all P<;.001). These mirrored results of patients <;65 years of age. Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]95% CI [P = .242]; 0.3 [0.1; 0.5]95% CI [P<;.001], and 11.8 [3.3; 42.8]95% CI [P<;.001] for DUAL II, V, and III, respectively). Conclusion: Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.
UR - http://www.scopus.com/inward/record.url?scp=85062431060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062431060&partnerID=8YFLogxK
U2 - 10.4158/EP-2018-0284
DO - 10.4158/EP-2018-0284
M3 - Article
C2 - 30383495
AN - SCOPUS:85062431060
SN - 1530-891X
VL - 25
SP - 144
EP - 155
JO - Endocrine Practice
JF - Endocrine Practice
IS - 2
ER -